For individuals suffering from a deadly disease, clinical trials for drugs offer lifesaving hope. But for all the rapid advances in science and medicine, some of the building blocks of clinical trials — the back-end technology, data aggregation and patient recruitment — haven’t changed much in decades.One start-up hopes to streamline the process. Paradigm, a company based in New York, is building technology that it says will make it easier for doctors, researchers and big pharmaceutical companies to carry out the often convoluted and messy work of clinical trials.Kent Thoelke, the chief executive of Paradigm, should know. Mr. Thoelke spent more than 25 years overseeing drug development and clinical trials at various health care companies and saw many of the inefficiencies firsthand.“I …
